Study of ESG401 in Adults With Solid Tumors
Ontology highlight
ABSTRACT: The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of ESG401 administered in 21-day treatment cycles at a dose selected in Phase I.
Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).
DISEASE(S): Neoplasms,ovarian,Neoplasms,colorectal,Neoplasms, Bladder,Urinary Bladder Neoplasms,Breast Neoplasms,Lung Neoplasms,Neoplasms, Breast,Neoplasm Of Stomach,Neoplasms,Colorectal Neoplasms,Neoplasms, Lung,Ovarian Neoplasms,Stomach Neoplasms
PROVIDER: 2377953 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA